CA2533903A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Download PDF

Info

Publication number
CA2533903A1
CA2533903A1 CA002533903A CA2533903A CA2533903A1 CA 2533903 A1 CA2533903 A1 CA 2533903A1 CA 002533903 A CA002533903 A CA 002533903A CA 2533903 A CA2533903 A CA 2533903A CA 2533903 A1 CA2533903 A1 CA 2533903A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
shows
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533903A
Other languages
English (en)
Inventor
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Paul J. Godowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Paul J. Godowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Application filed by Genentech, Inc., Kevin P. Baker, Jian Chen, Luc Desnoyers, Audrey Goddard, Austin L. Gurney, James Pan, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang, Paul J. Godowski filed Critical Genentech, Inc.
Publication of CA2533903A1 publication Critical patent/CA2533903A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002533903A 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Abandoned CA2533903A1 (fr)

Applications Claiming Priority (80)

Application Number Priority Date Filing Date Title
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05601 2000-03-01
USPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US18696800P 2000-03-06 2000-03-06
US60/186,968 2000-03-06
US18932000P 2000-03-14 2000-03-14
US18932800P 2000-03-14 2000-03-14
US60/189,328 2000-03-14
US60/189,320 2000-03-14
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
USPCT/US00/06884 2000-03-15
US19104800P 2000-03-21 2000-03-21
US19131400P 2000-03-21 2000-03-21
US19082800P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US60/190,828 2000-03-21
US60/191,007 2000-03-21
US60/191,314 2000-03-21
US60/191,048 2000-03-21
US19265500P 2000-03-28 2000-03-28
US60/192,655 2000-03-28
US19303200P 2000-03-29 2000-03-29
US19305300P 2000-03-29 2000-03-29
US60/193,032 2000-03-29
US60/193,053 2000-03-29
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19464700P 2000-04-04 2000-04-04
US19444900P 2000-04-04 2000-04-04
US60/194,449 2000-04-04
US60/194,647 2000-04-04
US19669000P 2000-04-11 2000-04-11
US19682000P 2000-04-11 2000-04-11
US19597500P 2000-04-11 2000-04-11
US19600000P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US60/196,690 2000-04-11
US60/196,187 2000-04-11
US60/195,975 2000-04-11
US60/196,000 2000-04-11
US60/196,820 2000-04-11
US19858500P 2000-04-18 2000-04-18
US19812100P 2000-04-18 2000-04-18
US60/198,585 2000-04-18
US60/198,121 2000-04-18
US19965400P 2000-04-25 2000-04-25
US19955000P 2000-04-25 2000-04-25
US19939700P 2000-04-25 2000-04-25
US60/199,654 2000-04-25
US60/199,550 2000-04-25
US60/199,397 2000-04-25
US20151600P 2000-05-03 2000-05-03
US60/201,516 2000-05-03
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/13705 2000-05-17
USPCT/US00/14042 2000-05-22
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14941 2000-05-30
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/15264 2000-06-02
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
US64484800A 2000-08-22 2000-08-22
US09/644,848 2000-08-22
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US60/000,000 2000-09-15
USPCT/US00/30952 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/34956 2000-12-20
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
CA002401448A CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002401448A Division CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Publications (1)

Publication Number Publication Date
CA2533903A1 true CA2533903A1 (fr) 2001-09-20

Family

ID=40231083

Family Applications (10)

Application Number Title Priority Date Filing Date
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications After (5)

Application Number Title Priority Date Filing Date
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2533991A1 (fr)
WO (1) WO2001068848A2 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
JP2001514885A (ja) 1997-08-19 2001-09-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７０個のヒト分泌タンパク質
EP1012179A2 (fr) 1997-09-12 2000-06-28 Apotech R&D S.A. Recepteurs "trail" riches en cysteine
EP1015488B1 (fr) * 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
AU5007200A (en) * 1999-05-13 2000-12-05 Medical Research Council Ox2 receptor homologs
EP1623993A3 (fr) * 1999-09-01 2006-06-07 Genetech, Inc. Protéines sécrétées et transmembranaire et acides nucléiques les codant
ATE364689T1 (de) 1999-11-18 2007-07-15 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
WO2002000857A2 (fr) * 2000-06-15 2002-01-03 Millennium Pharmaceuticals, Inc. Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
US20020155499A1 (en) * 2000-09-25 2002-10-24 Leiby Kevin R. 32624, a novel human UDP-glucuronosyl and glycosyl transferase family member and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001083781A2 (fr) 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
JP2004500872A (ja) * 2000-06-22 2004-01-15 バイオジェン　インコーポレイテッド Ｇｐ３５４核酸およびポリペプチド
US20020061574A1 (en) * 2000-09-01 2002-05-23 Rachel Meyers 16658, 14223, and 16002, novel human kinases and uses therefor
MXPA02012749A (es) * 2000-06-30 2003-10-06 Amgen Inc Moleculas semejantes a b7 y sus usos.
WO2002010217A2 (fr) 2000-08-02 2002-02-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
CA2420392A1 (fr) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 17 proteines humaines secretees
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
CA2440618A1 (fr) * 2001-03-12 2002-09-19 Incyte Genomics, Inc. Proteines de la superfamille des immunoglobulines
WO2002083921A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US7049096B2 (en) 2001-04-11 2006-05-23 Bristol-Meyers Squibb Company Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
CA2451271A1 (fr) * 2001-06-22 2003-01-03 Alexander V. Lukashin Acides nucleiques et polypeptides pancam
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
CA2453653A1 (fr) * 2001-07-26 2003-02-06 Genset S.A. Polynucleotides et polypeptides gmg-2 et leurs utilisations
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
WO2003018805A1 (fr) * 2001-08-23 2003-03-06 Japan Science And Technology Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
DE60238143D1 (de) * 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
JP2005508171A (ja) * 2001-11-02 2005-03-31 タノックス インコーポレーテッド Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原
AU2002359815A1 (en) 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2002254651A1 (en) * 2002-04-17 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
EP1514926A4 (fr) * 2002-05-31 2006-01-11 Hidetoshi Inoko Gene slurp-2 associe a une maladie de peau inflammatoire et utilisation de ce gene
WO2003102193A1 (fr) * 2002-05-31 2003-12-11 Seikagaku Corporation Chondroitine synthetase et acide nucleique codant pour cette enzyme
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
JP2006518582A (ja) * 2002-09-11 2006-08-17 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
DE10242016A1 (de) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20050085881A (ko) * 2002-12-26 2005-08-29 다케다 야쿠힌 고교 가부시키가이샤 신규 단백질 및 그 용도
WO2004063226A2 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
EP1588167A4 (fr) * 2003-01-16 2006-08-09 Univ Virginia Proteines lysozymoides specifiques du sperme
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
JP2007528721A (ja) 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
CA2551546A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
RU2007104022A (ru) 2004-07-02 2008-08-10 Дженентек, Инк. (Us) Композиции для лечения неходжкинской лимфомы и способы их применения
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
JP2008532516A (ja) * 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
US20090288176A1 (en) * 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US8003620B2 (en) 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
ES2625259T3 (es) 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
CA3138282A1 (fr) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Peptides derives de xbp1, cd138 et cs1
PT2403878T (pt) 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
EP2427203B1 (fr) 2009-05-05 2018-10-17 Novimmune S.A. Anticorps anti-il-17f et leurs utilisation
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
KR102381936B1 (ko) 2012-11-13 2022-04-01 비온테크 에스이 클라우딘 발현 암 질환의 치료제
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
EP4092119A3 (fr) 2015-07-10 2023-03-22 Ionis Pharmaceuticals, Inc. Modulateurs de diacylglycérol acyltransférase 2 (dgat2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO2002016429A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
EP1210418B1 (fr) * 1999-06-02 2010-08-18 Genentech, Inc. Polypeptides secretes et transmembranaires ainsi que les acides nucleiques codant pour ceux-ci
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001057190A2 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides

Also Published As

Publication number Publication date
CA2533991A1 (fr) 2001-09-20
WO2001068848A3 (fr) 2002-08-29
CA2534391A1 (fr) 2001-09-20
CA2539214A1 (fr) 2001-09-20
JP2004508805A (ja) 2004-03-25
JP2006081548A (ja) 2006-03-30
CA2534030A1 (fr) 2001-09-20
CA2534186A1 (fr) 2001-09-20
EP1259614A2 (fr) 2002-11-27
WO2001068848A2 (fr) 2001-09-20
AU2001268028A1 (en) 2001-09-24
AU6802801A (en) 2001-09-24
CA2401448A1 (fr) 2001-09-20
JP2008301822A (ja) 2008-12-18
CA2531917A1 (fr) 2001-09-20
CA2533831A1 (fr) 2001-09-20
CA2534018A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
US7189838B2 (en) PRO9834 nucleic acids
US7332573B2 (en) PRO1571 polypeptides
CA2533903A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US20030017541A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7084255B2 (en) PRO1278 polypeptides
US20040023321A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104548A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104547A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104551A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead